Effect of Pharmacogenomic Testing on Pediatric Mental Health Outcome: A 6-Month Follow-Up

References

• Merikangas KR , HeJP , BursteinMet al. Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication–Adolescent Supplement (NCS-A). J. Am. Acad. Child Adolesc. Psychiatry49(10), 980–989 (2010).
   PubMed Web of Science ®Google Scholar
• 2016 National Survey of Children’s Health (NSCH)Child and Adolescent Health Measurement Initiative. Data Resource Center for Child and Adolescent Health. 2016 (2016). www.childhealthdata.org CAHMI: www.cahmi.org.
   Google Scholar
• Strawn JR , DobsonET , GilesLL. Primary pediatric care psychopharmacology: focus on medications for ADHD, depression, and anxiety. Curr. Probl. Pediatr. Adolesc. Health Care47(1), 3–14 (2017).
   PubMed Web of Science ®Google Scholar
• Garland EJ , KutcherS , ViraniA , ElbeD. Update on the use of SSRIs and SNRIs with children and adolescents in clinical practice. J. Can. Acad. Child Adolesc. Psychiatry25(1), 4–10 (2016).
   PubMedGoogle Scholar
• A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal treatment study of children with ADHD. Arch. Gen. Psychiatry56(12), 1073–1086 (1999).
   PubMed Web of Science ®Google Scholar
• March J , SilvaS , PetryckiSet al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. JAMA292(7), 807–820 (2004).
   PubMed Web of Science ®Google Scholar
• Compton SN , PerisTS , AlmirallDet al. Predictors and moderators of treatment response in childhood anxiety disorders: results from the CAMS trial. J. Consult. Clin. Psychol.82(2), 212–224 (2014).
   PubMed Web of Science ®Google Scholar
• Howie LD , PastorPN , LukacsSL. Use of medication prescribed for emotional or behavioral difficulties among children aged 6–17 years in the United States, 2011–2012. NCHS Data Brief (148), 1–8 (2014).
   PubMedGoogle Scholar
• Dosreis S , MychailyszynMP , Evans-LackoSE , BeltranA , RileyAW , MyersMA. The meaning of attention-deficit/hyperactivity disorder medication and parents’ initiation and continuity of treatment for their child. J. Child. Adolesc. Psychopharmacol.19(4), 377–383 (2009).
   PubMed Web of Science ®Google Scholar
• Chang M , TybringG , DahlML , LindhJD. Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis. Clin. Pharmacokinet.53(9), 801–811 (2014).
   PubMed Web of Science ®Google Scholar
• Rush AJ , TrivediMH , WisniewskiSRet al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry163(11), 1905–1917 (2006).
   PubMed Web of Science ®Google Scholar
• Stephenson T . How children’s responses to drugs differ from adults. Br. J. Clin. Pharmacol.59(6), 670–673 (2005).
   PubMed Web of Science ®Google Scholar
• Guengerich FP . A history of the roles of cytochrome P450 enzymes in the toxicity of drugs. Toxicol. Res.37(1), 1–23 (2021).
   PubMed Web of Science ®Google Scholar
• Hiemke C , BaumannP , BergemannNet al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry44(6), 195–235 (2011).
   Web of Science ®Google Scholar
• Schoretsanitis G , PaulzenM , UntereckerSet al. TDM in psychiatry and neurology: a comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians. World J. Biol. Psychiatry19(3), 162–174 (2018).
   PubMed Web of Science ®Google Scholar
• Tracy TS , ChaudhryAS , PrasadBet al. Interindividual variability in cytochrome P450-mediated drug metabolism. Drug Metab. Dispos.44(3), 343–351 (2016).
   PubMed Web of Science ®Google Scholar
• Leeder JS , KearnsGL. Pharmacogenetics in pediatrics. Implications for practice. Pediatr. Clin. North Am.44(1), 55–77 (1997).
   PubMed Web of Science ®Google Scholar
• Wehry AM , RamseyL , DulembaSE , MossmanSA , StrawnJR. Pharmacogenomic testing in child and adolescent psychiatry: an evidence-based review. Curr. Probl. Pediatr. Adolesc. Health Care48(2), 40–49 (2018).
   PubMed Web of Science ®Google Scholar
• Guengerich FP . Cytochrome p450 and chemical toxicology. Chem. Res. Toxicol.21(1), 70–83 (2008).
   PubMed Web of Science ®Google Scholar
• Pacifici GM , PelkonenRO. Interindividual Variability in Human Drug Metabolism.Taylor & Francis, London, UK (2001).
   Google Scholar
• Shirasaka Y , ChaudhryAS , McDonaldMet al. Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content. Pharmacogenomics J.16(4), 375–387 (2016).
   PubMed Web of Science ®Google Scholar
• Zandi PP , JudyJT. The promise and reality of pharmacogenetics in psychiatry. Psychiatr. Clin. North Am.33(1), 181–224 (2010).
   PubMed Web of Science ®Google Scholar
• Bradley P , ShiekhM , MehraVet al. Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: a randomized clinical trial demonstrating clinical utility. J. Psychiatr. Res.96, 100–107 (2018).
   PubMed Web of Science ®Google Scholar
• Pisanu C , HeilbronnerU , SquassinaA. The role of pharmacogenomics in bipolar disorder: moving towards precision medicine. Mol. Diagn. Ther.22(4), 409–420 (2018).
   PubMed Web of Science ®Google Scholar
• Gregornik D , SalyakinaD , BrownM , RoikoS , RamosK. Pediatric pharmacogenomics: challenges and opportunities: on behalf of the Sanford Children’s Genomic Medicine Consortium. Pharmacogenomics J.21(1), 8–19 (2021).
   PubMed Web of Science ®Google Scholar
• Rosenblat JD , LeeY , McIntyreRS. Does pharmacogenomic testing improve clinical outcomes for major depressive disorder? A systematic review of clinical trials and cost–effectiveness studies. J. Clin. Psychiatry78(6), 720–729 (2017).
   PubMed Web of Science ®Google Scholar
• Blazquez A , MasS , PlanaMT , LafuenteA , LazaroL. Fluoxetine pharmacogenetics in child and adult populations. Eur. Child Adolesc. Psychiatry21(11), 599–610 (2012).
   PubMed Web of Science ®Google Scholar
• Gasso P , BlazquezA , RodriguezNet al. Further support for the involvement of genetic variants related to the serotonergic pathway in the antidepressant response in children and adolescents after a 12-month follow-up: impact of the HTR2A rs7997012 Polymorphism. J. Child. Adolesc. Psychopharmacol.28(10), 711–718 (2018).
   PubMed Web of Science ®Google Scholar
• Myer NM , BolandJR , FaraoneSV. Pharmacogenetics predictors of methylphenidate efficacy in childhood ADHD. Mol. Psychiatry23(9), 1929–1936 (2018).
   PubMed Web of Science ®Google Scholar
• Cheon KA , JunJY , ChoDY. Association of the catechol-O-methyltransferase polymorphism with methylphenidate response in a classroom setting in children with attention-deficit hyperactivity disorder. Int. Clin. Psychopharmacol.23(5), 291–298 (2008).
   PubMed Web of Science ®Google Scholar
• Cohn I , ManshaeiR , ListonEet al. Assessment of the implementation of pharmacogenomic testing in a pediatric tertiary care setting. JAMA Netw. Open4(5), e2110446 (2021).
   PubMed Web of Science ®Google Scholar
• Blasco-Fontecilla H . Clinical utility of pharmacogenetic testing in children and adolescents with severe mental disorders. J. Neural Transm. (Vienna)126(1), 101–107 (2019).
   PubMed Web of Science ®Google Scholar
• Aldrich SL , PoweleitEA , ProwsCA , MartinLJ , StrawnJR , RamseyLB. Influence of CYP2C19 metabolizer status on escitalopram/citalopram tolerability and response in youth with anxiety and depressive disorders. Front. Pharmacol.10, 99 (2019).
   PubMed Web of Science ®Google Scholar
• Winner JG , CarhartJM , AltarCA , AllenJD , DechairoBM. A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. Discov. Med.16(89), 219–227 (2013).
   PubMed Web of Science ®Google Scholar
• Ghandour RM , ShermanLJ , VladutiuCJet al. Prevalence and treatment of depression, anxiety, and conduct problems in US children. J. Pediatr.206, 256–267 e253 (2019).
   PubMed Web of Science ®Google Scholar
• Kessler RC , McGonagleKA , ZhaoSet al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry51(1), 8–19 (1994).
   PubMed Web of Science ®Google Scholar
• Saveanu RV , NemeroffCB. Etiology of depression: genetic and environmental factors. Psychiatr. Clin. North Am.35(1), 51–71 (2012).
   PubMed Web of Science ®Google Scholar
• Bandelow B , MichaelisS , WedekindD. Treatment of anxiety disorders. Dialogues Clin. Neurosci.19(2), 93–107 (2017).
   PubMed Web of Science ®Google Scholar
• Azeredo A , MoreiraD , BarbosaF. ADHD, CD, and ODD: systematic review of genetic and environmental risk factors. Res. Dev. Disabil.82, 10–19 (2018).
   PubMed Web of Science ®Google Scholar
• Fuchs T . Subjectivity and intersubjectivity in psychiatric diagnosis. Psychopathology43(4), 268–274 (2010).
   PubMed Web of Science ®Google Scholar
• Walkup JT . Antidepressant efficacy for depression in children and adolescents: industry- and NIMH-funded studies. Am. J. Psychiatry174(5), 430–437 (2017).
   PubMed Web of Science ®Google Scholar
• Cipriani A , ZhouX , DelGiovane Cet al. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet388(10047), 881–890 (2016).
   PubMed Web of Science ®Google Scholar
• Strawn JR , WelgeJA , WehryAM , KeeshinB , RynnMA. Efficacy and tolerability of antidepressants in pediatric anxiety disorders: a systematic review and meta-analysis. Depress. Anxiety32(3), 149–157 (2015).
   PubMed Web of Science ®Google Scholar
• Blackburn TP . Depressive disorders: treatment failures and poor prognosis over the last 50 years. Pharmacol. Res. Perspect.7(3), e00472 (2019).
   PubMed Web of Science ®Google Scholar
• Elsayed NA , YamamotoKM , FroehlichTE. Genetic influence on efficacy of pharmacotherapy for pediatric attention-deficit/hyperactivity disorder: overview and current status of research. CNS Drugs34(4), 389–414 (2020).
   PubMed Web of Science ®Google Scholar
• Chen J , LipskaBK , HalimNet al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am. J. Hum. Genet.75(5), 807–821 (2004).
   PubMed Web of Science ®Google Scholar
• Seamans JK , YangCR. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog. Neurobiol.74(1), 1–58 (2004).
   PubMed Web of Science ®Google Scholar
• Zhu G , LipskyRH , XuKet al. Differential expression of human COMT alleles in brain and lymphoblasts detected by RT-coupled 5′ nuclease assay. Psychopharmacology (Berl.)177(1–2), 178–184 (2004).
   PubMed Web of Science ®Google Scholar
• Gothelf D , PresburgerG , LevyDet al. Genetic, developmental, and physical factors associated with attention deficit hyperactivity disorder in patients with velocardiofacial syndrome. Am. J. Med. Genet. B Neuropsychiatr. Genet.126B(1), 116–121 (2004).
   PubMed Web of Science ®Google Scholar
• Gothelf D , MichaelovskyE , FrischAet al. Association of the low-activity COMT 158Met allele with ADHD and OCD in subjects with velocardiofacial syndrome. Int. J. Neuropsychopharmacol.10(3), 301–308 (2007).
   PubMed Web of Science ®Google Scholar
• Greden JF , ParikhSV , RothschildAJet al. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: a large, patient- and rater-blinded, randomized, controlled study. J. Psychiatr. Res.111, 59–67 (2019).
   PubMed Web of Science ®Google Scholar
• Hathaway EE , WalkupJT , StrawnJR. Antidepressant treatment duration in pediatric depressive and anxiety disorders: how long is long enough?Curr. Probl. Pediatr. Adolesc. Health Care48(2), 31–39 (2018).
   PubMed Web of Science ®Google Scholar
• Verbelen M , WealeME , LewisCM. Cost–effectiveness of pharmacogenetic-guided treatment: are we there yet?Pharmacogenomics J.17(5), 395–402 (2017).
   PubMed Web of Science ®Google Scholar